AngioDynamics, Inc. announced that as a result of lower than anticipated AngioVac sales, management now expects the Company's fiscal year 2023 net sales to be in the range of $338 million to $342 million, a decrease from its prior guidance of $342 million to $348 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.87 USD | +2.98% | +5.01% | -25.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.13% | 227M | |
+3.26% | 197B | |
+5.79% | 115B | |
+1.48% | 71.22B | |
+11.77% | 53.77B | |
+18.31% | 48.75B | |
+6.87% | 44.22B | |
+12.38% | 28.85B | |
+9.76% | 28.57B | |
+10.35% | 27.62B |
- Stock
- Equities
- Stock AngioDynamics, Inc. - Nasdaq
- News AngioDynamics, Inc.
- Angiodynamics, Inc. Revised Revenue Guidance for the Fiscal 2023